Natalie Nicelli represents and counsels pharmaceutical, biotechnology, medical device, diagnostics, and other life science companies, from early-stage start-ups to multinational corporations. Natalie’s practice includes structuring and negotiating complex collaborations, licensing transactions, master services agreements, clinical trial agreements, manufacturing, supply, distribution and commercialization agreements, and other strategic partnering arrangements, including joint ventures. While in law school, Natalie served as a member of the NYU Review of Law & Social Change.
Eli Lilly and Company in its collaboration agreement valued up to $1 billion with Evotec for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases
Merck in its agreement with Gilead to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV
Regeneron in its license and collaboration agreement with Nykode Therapeutics for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases
Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity
Nevakar in its exclusive licensing agreement for the commercialization of NVK-002, a proprietary, investigational, preservative-free eye drop to treat myopia in children ages three to 17, valued up to $135 million with Laboratoires Théa
Vyera Pharmaceuticals, LLC in its collaboration with CytoDyn Inc. for the commercialization and licensing of leronlimab, a viral-entry inhibitor for the treatment of HIV in which Vyera will pay upfront, regulatory and sales-based milestones totaling $86.5 million, as well as a royalty on net sales of 50 percent, and Vyera will purchase $4 million of CytoDyn common stock